Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma

Purpose To determine whether whole pelvic radiotherapy (WPRT) or prostate-only radiotherapy (PORT) yields improved biochemical disease-free survival (BDFS) in patients with advanced or aggressive prostate adenocarcinoma. Methods and Materials Between 2000 and 2007, a consecutive sample of 277 patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 2009-12, Vol.75 (5), p.1344-1349
Hauptverfasser: Aizer, Ayal A., B.S, Yu, James B., M.D, McKeon, Anne M., B.S, Decker, Roy H., M.D., Ph.D, Colberg, John W., M.D, Peschel, Richard E., M.D., Ph.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1349
container_issue 5
container_start_page 1344
container_title International journal of radiation oncology, biology, physics
container_volume 75
creator Aizer, Ayal A., B.S
Yu, James B., M.D
McKeon, Anne M., B.S
Decker, Roy H., M.D., Ph.D
Colberg, John W., M.D
Peschel, Richard E., M.D., Ph.D
description Purpose To determine whether whole pelvic radiotherapy (WPRT) or prostate-only radiotherapy (PORT) yields improved biochemical disease-free survival (BDFS) in patients with advanced or aggressive prostate adenocarcinoma. Methods and Materials Between 2000 and 2007, a consecutive sample of 277 patients with prostate adenocarcinoma and at least a 15% likelihood of lymph node involvement who had undergone WPRT ( n = 68) or PORT ( n = 209) at two referral centers was analyzed. The median radiation dose in both arms was 75.6 Gy. The outcome measure was BDFS, as determined using the prostate-specific antigen nadir + 2 ng/mL definition of failure. BDFS was calculated using the Kaplan-Meier method and compared with the log–rank test. A multivariate analysis was performed to assess for confounding. Treatment-related toxicity was assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events guidelines. The median follow-up was 30 months. Results WPRT patients had more advanced and aggressive disease at baseline ( p < .001). The 4-year BDFS rate was 69.4% in the PORT cohort and 86.3% in the WPRT cohort ( p = .02). Within the entire cohort, after adjustment for confounding variables, the pretreatment prostate-specific antigen ( p < .001), Gleason score ( p < .001), use of hormonal therapy ( p = .002), and use of WPRT (vs. PORT, p = .006) predicted for BDFS. Patients undergoing WPRT had increased acute gastrointestinal toxicity ( p = .048), but no significant difference in acute genitourinary toxicity was seen ( p = .09). No difference in late toxicity was found. Conclusion WPRT may yield improved BDFS in patients with advanced or aggressive prostate adenocarcinoma, but results in a greater incidence of acute toxicity.
doi_str_mv 10.1016/j.ijrobp.2008.12.082
format Article
fullrecord <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21367540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301609002041</els_id><sourcerecordid>21030176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-51c1198aef34dbe44f0746927c36278975bd9c9e9c5063322e4d9aa329263d373</originalsourceid><addsrcrecordid>eNqFkkuLFDEUhQtRnJ7RfyASENxVmVc9shGaQR2hZQbfu5BObnWnrEp6kqqG_gX-bVNUw6AbV8niOyc359wse0FwQTCp3nSF7YLfHgqKcVMQWuCGPspWpKlFzsry5-NshVmFc5bgi-wyxg5jTEjNn2YXRPCKN5Ssst8_9r4HdAf90Wr0WRnrxz0EdTih7xDiFNFd8HFUI6Bb15_-JqxD6Yo-Kad2MIAbkW_RxmvVJ3JtjsppMMgHtN7tAsRoj_BgtzbgEhq0dX5Qz7InreojPD-fV9m39---Xt_km9sPH6_Xm1zzuhzzkmhCRKOgZdxsgfMW17wStNasonUj6nJrhBYgdIkrxigFboRSjApaMcNqdpW9WnzTFFZGbUfQe-2dAz1KSlhVlxwn6vVCHYK_nyCOcrBRQ98rB36KCcQp1rpKIF9Anb4VA7TyEOygwkkSLOeaZCeXmuRckyRUppqS7OXZf9oOYB5E514S8HYBIGVxtBDmUWGO04Z5UuPt_17410D31tlUzS84Qez8FFzKWRIZk0B-mVdl3hQsMKaYE_YHxRe7Mw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21030176</pqid></control><display><type>article</type><title>Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Aizer, Ayal A., B.S ; Yu, James B., M.D ; McKeon, Anne M., B.S ; Decker, Roy H., M.D., Ph.D ; Colberg, John W., M.D ; Peschel, Richard E., M.D., Ph.D</creator><creatorcontrib>Aizer, Ayal A., B.S ; Yu, James B., M.D ; McKeon, Anne M., B.S ; Decker, Roy H., M.D., Ph.D ; Colberg, John W., M.D ; Peschel, Richard E., M.D., Ph.D</creatorcontrib><description>Purpose To determine whether whole pelvic radiotherapy (WPRT) or prostate-only radiotherapy (PORT) yields improved biochemical disease-free survival (BDFS) in patients with advanced or aggressive prostate adenocarcinoma. Methods and Materials Between 2000 and 2007, a consecutive sample of 277 patients with prostate adenocarcinoma and at least a 15% likelihood of lymph node involvement who had undergone WPRT ( n = 68) or PORT ( n = 209) at two referral centers was analyzed. The median radiation dose in both arms was 75.6 Gy. The outcome measure was BDFS, as determined using the prostate-specific antigen nadir + 2 ng/mL definition of failure. BDFS was calculated using the Kaplan-Meier method and compared with the log–rank test. A multivariate analysis was performed to assess for confounding. Treatment-related toxicity was assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events guidelines. The median follow-up was 30 months. Results WPRT patients had more advanced and aggressive disease at baseline ( p &lt; .001). The 4-year BDFS rate was 69.4% in the PORT cohort and 86.3% in the WPRT cohort ( p = .02). Within the entire cohort, after adjustment for confounding variables, the pretreatment prostate-specific antigen ( p &lt; .001), Gleason score ( p &lt; .001), use of hormonal therapy ( p = .002), and use of WPRT (vs. PORT, p = .006) predicted for BDFS. Patients undergoing WPRT had increased acute gastrointestinal toxicity ( p = .048), but no significant difference in acute genitourinary toxicity was seen ( p = .09). No difference in late toxicity was found. Conclusion WPRT may yield improved BDFS in patients with advanced or aggressive prostate adenocarcinoma, but results in a greater incidence of acute toxicity.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2008.12.082</identifier><identifier>PMID: 19464821</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>adenocarcinoma ; Adenocarcinoma - blood ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - radiotherapy ; Aged ; BODY ; cancer ; CARCINOMAS ; Disease-Free Survival ; DISEASES ; Follow-Up Studies ; Gastrointestinal Tract - radiation effects ; GLANDS ; Hematology, Oncology and Palliative Medicine ; Humans ; Lymphatic Irradiation - adverse effects ; Lymphatic Irradiation - methods ; Lymphatic Metastasis - radiotherapy ; Male ; MALE GENITALS ; MATHEMATICS ; MEDICINE ; Middle Aged ; MULTIVARIATE ANALYSIS ; NEOPLASMS ; NUCLEAR MEDICINE ; ORGANS ; PELVIS ; PROSTATE ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; RADIOLOGY ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy Dosage ; Radiotherapy, Intensity-Modulated - adverse effects ; Radiotherapy, Intensity-Modulated - methods ; Retrospective Studies ; STATISTICS ; THERAPY ; TOXICITY ; Urogenital System - radiation effects ; whole pelvic</subject><ispartof>International journal of radiation oncology, biology, physics, 2009-12, Vol.75 (5), p.1344-1349</ispartof><rights>Elsevier Inc.</rights><rights>2009 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-51c1198aef34dbe44f0746927c36278975bd9c9e9c5063322e4d9aa329263d373</citedby><cites>FETCH-LOGICAL-c475t-51c1198aef34dbe44f0746927c36278975bd9c9e9c5063322e4d9aa329263d373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2008.12.082$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19464821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21367540$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Aizer, Ayal A., B.S</creatorcontrib><creatorcontrib>Yu, James B., M.D</creatorcontrib><creatorcontrib>McKeon, Anne M., B.S</creatorcontrib><creatorcontrib>Decker, Roy H., M.D., Ph.D</creatorcontrib><creatorcontrib>Colberg, John W., M.D</creatorcontrib><creatorcontrib>Peschel, Richard E., M.D., Ph.D</creatorcontrib><title>Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To determine whether whole pelvic radiotherapy (WPRT) or prostate-only radiotherapy (PORT) yields improved biochemical disease-free survival (BDFS) in patients with advanced or aggressive prostate adenocarcinoma. Methods and Materials Between 2000 and 2007, a consecutive sample of 277 patients with prostate adenocarcinoma and at least a 15% likelihood of lymph node involvement who had undergone WPRT ( n = 68) or PORT ( n = 209) at two referral centers was analyzed. The median radiation dose in both arms was 75.6 Gy. The outcome measure was BDFS, as determined using the prostate-specific antigen nadir + 2 ng/mL definition of failure. BDFS was calculated using the Kaplan-Meier method and compared with the log–rank test. A multivariate analysis was performed to assess for confounding. Treatment-related toxicity was assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events guidelines. The median follow-up was 30 months. Results WPRT patients had more advanced and aggressive disease at baseline ( p &lt; .001). The 4-year BDFS rate was 69.4% in the PORT cohort and 86.3% in the WPRT cohort ( p = .02). Within the entire cohort, after adjustment for confounding variables, the pretreatment prostate-specific antigen ( p &lt; .001), Gleason score ( p &lt; .001), use of hormonal therapy ( p = .002), and use of WPRT (vs. PORT, p = .006) predicted for BDFS. Patients undergoing WPRT had increased acute gastrointestinal toxicity ( p = .048), but no significant difference in acute genitourinary toxicity was seen ( p = .09). No difference in late toxicity was found. Conclusion WPRT may yield improved BDFS in patients with advanced or aggressive prostate adenocarcinoma, but results in a greater incidence of acute toxicity.</description><subject>adenocarcinoma</subject><subject>Adenocarcinoma - blood</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Aged</subject><subject>BODY</subject><subject>cancer</subject><subject>CARCINOMAS</subject><subject>Disease-Free Survival</subject><subject>DISEASES</subject><subject>Follow-Up Studies</subject><subject>Gastrointestinal Tract - radiation effects</subject><subject>GLANDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lymphatic Irradiation - adverse effects</subject><subject>Lymphatic Irradiation - methods</subject><subject>Lymphatic Metastasis - radiotherapy</subject><subject>Male</subject><subject>MALE GENITALS</subject><subject>MATHEMATICS</subject><subject>MEDICINE</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>NEOPLASMS</subject><subject>NUCLEAR MEDICINE</subject><subject>ORGANS</subject><subject>PELVIS</subject><subject>PROSTATE</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>RADIOLOGY</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Intensity-Modulated - adverse effects</subject><subject>Radiotherapy, Intensity-Modulated - methods</subject><subject>Retrospective Studies</subject><subject>STATISTICS</subject><subject>THERAPY</subject><subject>TOXICITY</subject><subject>Urogenital System - radiation effects</subject><subject>whole pelvic</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkkuLFDEUhQtRnJ7RfyASENxVmVc9shGaQR2hZQbfu5BObnWnrEp6kqqG_gX-bVNUw6AbV8niOyc359wse0FwQTCp3nSF7YLfHgqKcVMQWuCGPspWpKlFzsry5-NshVmFc5bgi-wyxg5jTEjNn2YXRPCKN5Ssst8_9r4HdAf90Wr0WRnrxz0EdTih7xDiFNFd8HFUI6Bb15_-JqxD6Yo-Kad2MIAbkW_RxmvVJ3JtjsppMMgHtN7tAsRoj_BgtzbgEhq0dX5Qz7InreojPD-fV9m39---Xt_km9sPH6_Xm1zzuhzzkmhCRKOgZdxsgfMW17wStNasonUj6nJrhBYgdIkrxigFboRSjApaMcNqdpW9WnzTFFZGbUfQe-2dAz1KSlhVlxwn6vVCHYK_nyCOcrBRQ98rB36KCcQp1rpKIF9Anb4VA7TyEOygwkkSLOeaZCeXmuRckyRUppqS7OXZf9oOYB5E514S8HYBIGVxtBDmUWGO04Z5UuPt_17410D31tlUzS84Qez8FFzKWRIZk0B-mVdl3hQsMKaYE_YHxRe7Mw</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Aizer, Ayal A., B.S</creator><creator>Yu, James B., M.D</creator><creator>McKeon, Anne M., B.S</creator><creator>Decker, Roy H., M.D., Ph.D</creator><creator>Colberg, John W., M.D</creator><creator>Peschel, Richard E., M.D., Ph.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20091201</creationdate><title>Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma</title><author>Aizer, Ayal A., B.S ; Yu, James B., M.D ; McKeon, Anne M., B.S ; Decker, Roy H., M.D., Ph.D ; Colberg, John W., M.D ; Peschel, Richard E., M.D., Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-51c1198aef34dbe44f0746927c36278975bd9c9e9c5063322e4d9aa329263d373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>adenocarcinoma</topic><topic>Adenocarcinoma - blood</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Aged</topic><topic>BODY</topic><topic>cancer</topic><topic>CARCINOMAS</topic><topic>Disease-Free Survival</topic><topic>DISEASES</topic><topic>Follow-Up Studies</topic><topic>Gastrointestinal Tract - radiation effects</topic><topic>GLANDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lymphatic Irradiation - adverse effects</topic><topic>Lymphatic Irradiation - methods</topic><topic>Lymphatic Metastasis - radiotherapy</topic><topic>Male</topic><topic>MALE GENITALS</topic><topic>MATHEMATICS</topic><topic>MEDICINE</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>NEOPLASMS</topic><topic>NUCLEAR MEDICINE</topic><topic>ORGANS</topic><topic>PELVIS</topic><topic>PROSTATE</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>RADIOLOGY</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Intensity-Modulated - adverse effects</topic><topic>Radiotherapy, Intensity-Modulated - methods</topic><topic>Retrospective Studies</topic><topic>STATISTICS</topic><topic>THERAPY</topic><topic>TOXICITY</topic><topic>Urogenital System - radiation effects</topic><topic>whole pelvic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aizer, Ayal A., B.S</creatorcontrib><creatorcontrib>Yu, James B., M.D</creatorcontrib><creatorcontrib>McKeon, Anne M., B.S</creatorcontrib><creatorcontrib>Decker, Roy H., M.D., Ph.D</creatorcontrib><creatorcontrib>Colberg, John W., M.D</creatorcontrib><creatorcontrib>Peschel, Richard E., M.D., Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aizer, Ayal A., B.S</au><au>Yu, James B., M.D</au><au>McKeon, Anne M., B.S</au><au>Decker, Roy H., M.D., Ph.D</au><au>Colberg, John W., M.D</au><au>Peschel, Richard E., M.D., Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>75</volume><issue>5</issue><spage>1344</spage><epage>1349</epage><pages>1344-1349</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose To determine whether whole pelvic radiotherapy (WPRT) or prostate-only radiotherapy (PORT) yields improved biochemical disease-free survival (BDFS) in patients with advanced or aggressive prostate adenocarcinoma. Methods and Materials Between 2000 and 2007, a consecutive sample of 277 patients with prostate adenocarcinoma and at least a 15% likelihood of lymph node involvement who had undergone WPRT ( n = 68) or PORT ( n = 209) at two referral centers was analyzed. The median radiation dose in both arms was 75.6 Gy. The outcome measure was BDFS, as determined using the prostate-specific antigen nadir + 2 ng/mL definition of failure. BDFS was calculated using the Kaplan-Meier method and compared with the log–rank test. A multivariate analysis was performed to assess for confounding. Treatment-related toxicity was assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events guidelines. The median follow-up was 30 months. Results WPRT patients had more advanced and aggressive disease at baseline ( p &lt; .001). The 4-year BDFS rate was 69.4% in the PORT cohort and 86.3% in the WPRT cohort ( p = .02). Within the entire cohort, after adjustment for confounding variables, the pretreatment prostate-specific antigen ( p &lt; .001), Gleason score ( p &lt; .001), use of hormonal therapy ( p = .002), and use of WPRT (vs. PORT, p = .006) predicted for BDFS. Patients undergoing WPRT had increased acute gastrointestinal toxicity ( p = .048), but no significant difference in acute genitourinary toxicity was seen ( p = .09). No difference in late toxicity was found. Conclusion WPRT may yield improved BDFS in patients with advanced or aggressive prostate adenocarcinoma, but results in a greater incidence of acute toxicity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19464821</pmid><doi>10.1016/j.ijrobp.2008.12.082</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0360-3016
ispartof International journal of radiation oncology, biology, physics, 2009-12, Vol.75 (5), p.1344-1349
issn 0360-3016
1879-355X
language eng
recordid cdi_osti_scitechconnect_21367540
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects adenocarcinoma
Adenocarcinoma - blood
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - radiotherapy
Aged
BODY
cancer
CARCINOMAS
Disease-Free Survival
DISEASES
Follow-Up Studies
Gastrointestinal Tract - radiation effects
GLANDS
Hematology, Oncology and Palliative Medicine
Humans
Lymphatic Irradiation - adverse effects
Lymphatic Irradiation - methods
Lymphatic Metastasis - radiotherapy
Male
MALE GENITALS
MATHEMATICS
MEDICINE
Middle Aged
MULTIVARIATE ANALYSIS
NEOPLASMS
NUCLEAR MEDICINE
ORGANS
PELVIS
PROSTATE
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - radiotherapy
RADIOLOGY
RADIOLOGY AND NUCLEAR MEDICINE
RADIOTHERAPY
Radiotherapy Dosage
Radiotherapy, Intensity-Modulated - adverse effects
Radiotherapy, Intensity-Modulated - methods
Retrospective Studies
STATISTICS
THERAPY
TOXICITY
Urogenital System - radiation effects
whole pelvic
title Whole Pelvic Radiotherapy Versus Prostate Only Radiotherapy in the Management of Locally Advanced or Aggressive Prostate Adenocarcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A05%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Whole%20Pelvic%20Radiotherapy%20Versus%20Prostate%20Only%20Radiotherapy%20in%20the%20Management%20of%20Locally%20Advanced%20or%20Aggressive%20Prostate%20Adenocarcinoma&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Aizer,%20Ayal%20A.,%20B.S&rft.date=2009-12-01&rft.volume=75&rft.issue=5&rft.spage=1344&rft.epage=1349&rft.pages=1344-1349&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2008.12.082&rft_dat=%3Cproquest_osti_%3E21030176%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21030176&rft_id=info:pmid/19464821&rft_els_id=1_s2_0_S0360301609002041&rfr_iscdi=true